Could Fast2Clinic™ get your inhaled programme to Phase I faster?
Fast2Clinic helps pharma and biotech companies move inhaled drug products into Phase 1 clinical studies faster. Our integrated clinical study support and inhalation formulation expertise help reduce development timelines and accelerate early proof of concept studies.
If your molecule is ready but your manufacturing timeline is not, we should talk.